'Today we have an award-winning pipeline of more than 25 promising new molecules,' said Dr.
FMC will use Ligand Design and Ligand Express, Cyclica's proprietary AI platforms, to optimize the discovery of novel compounds at a pace that far exceeds typical chemistry discovery research programs. Powered by MatchMaker, a deep learning proteome screening technology, and POEM, a machine learning technology for predicting molecular properties, Ligand Design and Ligand Express will assess millions of chemical structures, providing FMC researchers with a greater volume of high-quality molecule predictions that are specific to the pesticidal target of interest. A similar AI-augmented approach to discovery research has been used successfully for years in industries that require extensive data analysis, significant investments and lengthy development timelines, such as pharmaceuticals and healthcare.
'We are excited to partner with FMC scientists in their quest to innovate novel molecules that control pests and diseases in agriculture,' says
FMC's R&D team of more than 800 scientists and associates are guiding one of the most robust discovery and development pipelines in the agricultural industry at 22 innovation centers and field stations around the world. The company's global R&D is headquartered at the
Terms of the collaboration with Cyclica are not disclosed.
About FMC
FMC, the FMC logo, Rynaxypyr, Cyazypyr, Authority, Boral, Centium, Command, Gamit, Talstar, Hero, Quartzo and Presence are trademarks of
About
Cyclica is the first company to approach polypharmacology with a structure-based, AI-augmented in silico discovery platform, centered on Ligand Design and Ligand Express. Powered by MatchMaker, a proprietary deep learning proteome screening technology, and POEM, an innovative supervised learning technology for predicting molecular properties, Cyclica's platform is suited uniquely to the design of novel, chemical matter by simultaneously prioritizing compounds based on their on- and off-target polypharmacological profiles as well as their developmental properties. With a world-class team that has deep roots in the industry, a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs.
Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which are based on management's current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These factors include, among other things, the risk factors and other cautionary statements included within FMC's 2019 Form 10-K filed with the
SOURCE
FMC Media contact,
(C) 2020 Electronic News Publishing, source